Suppr超能文献

格雷夫斯病体外白细胞介素-2产生缺陷的调节

Modulation of the IL-2 production defect in vitro in Graves' disease.

作者信息

Eisenstein Z, Engelsman E, Weiss M, Kalechman Y, Sredni B

机构信息

Department of Medicine, Sheba Medical Centre, Tel-Hashomer, Israel.

出版信息

Clin Exp Immunol. 1994 May;96(2):323-8. doi: 10.1111/j.1365-2249.1994.tb06561.x.

Abstract

IL-2 production by mitogen-induced peripheral blood mononuclear cells was reported to be reduced in several autoimmune diseases, including Graves' disease (GD). This production defect in hyperthyroid GD was restored to normal by antithyroid drug therapy or during remission. However, its underlying mechanism and role in the autoimmune process are still uncertain. The present study was undertaken in order to screen the in vitro IL-2 generating system for putative factors responsible for its failure, and to see to what extent this was reversible. Thyroid hormone or antithyroid drugs had no effect on IL-2 production in vitro. Cultures were found to be free of soluble inhibitors of IL-2 production or action. IL-1 deficiency as a cause of the IL-2 defect was ruled out; rather, Graves' adherent cells were found to be activated in being capable of secreting large amounts of IL-1 and prostaglandin E2 (PGE2). The latter was not found to be responsible for the decreased IL-2 production. IL-2 production by Graves' mononuclears was completely restored to normal by: (i) adherent cell depletion, irradiation or substitution with normal adherent cells; (ii) preincubation of mononuclears for 24-72 h before mitogen stimulation; (iii) the synergistic action of a phorbol ester and a calcium ionophore. These data indicate that inhibition by activated adherent cells accounts for the in vitro IL-2 production defect in GD. This inhibition is not mediated by soluble factors, but probably through direct interaction with the producing cells, and is reversible in rested cultures or through a bypassed signal transduction.

摘要

据报道,在包括格雷夫斯病(GD)在内的几种自身免疫性疾病中,丝裂原诱导的外周血单个核细胞产生白细胞介素-2(IL-2)的能力会降低。甲状腺功能亢进的GD患者中这种产生缺陷可通过抗甲状腺药物治疗或在缓解期恢复正常。然而,其潜在机制及其在自身免疫过程中的作用仍不确定。本研究旨在筛选体外IL-2产生系统中导致其功能障碍的假定因素,并观察其可逆程度。甲状腺激素或抗甲状腺药物对体外IL-2的产生没有影响。发现培养物中不存在IL-2产生或作用的可溶性抑制剂。排除了IL-1缺乏作为IL-2缺陷原因的可能性;相反,发现格雷夫斯病的贴壁细胞被激活,能够分泌大量的IL-1和前列腺素E2(PGE2)。未发现后者是导致IL-2产生减少的原因。格雷夫斯病单个核细胞产生IL-2的能力可通过以下方式完全恢复正常:(i)去除贴壁细胞、照射或用正常贴壁细胞替代;(ii)在丝裂原刺激前将单个核细胞预孵育24 - 72小时;(iii)佛波酯和钙离子载体的协同作用。这些数据表明,激活的贴壁细胞的抑制作用导致了GD患者体外IL-2产生缺陷。这种抑制不是由可溶性因子介导的,可能是通过与产生细胞的直接相互作用,并且在静止培养物中或通过旁路信号转导是可逆的。

相似文献

本文引用的文献

4
Studies of thyroid hormone and methimazole levels in patients with Graves' disease on a standardized anti-thyroid drug regimen.
Clin Endocrinol (Oxf). 1981 Jun;14(6):555-62. doi: 10.1111/j.1365-2265.1981.tb02965.x.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验